New rapid detection of type 1 diabetes nanochips
Recently, scientists at Stanford University School of Medicine have invented an inexpensive portable microchip detection technology for the diagnosis of type 1 diabetes, which is expected to improve the care of diabetic patients worldwide and help researchers better understand the disease. The results of the study were published in the July 13, 2014 issue of Nature Medicine. The researchers described the diagnostic method in Nature Medicine on July 13, 2014, which uses nanotechnology to detect type 1 diabetes outside the hospital setting. This handheld microchip distinguishes between two main forms of diabetes, type 1 and type 2 diabetes, which are characterized by hyperglycemia but with different causes and treatments. Until now, the distinction between these two types of diabetes requires a slow and expensive test and can only be achieved in complex health care facilities. Dr. Brian Feldman, Assistant Professor of Pediatric Endocrinology, is a senior author of this article and a pediatric endocrinologist at Lucile Packard Children's Hospital, Stanford University. He pointed out: "With this new method, we hope to not only be more effective and more widely diagnosed. Diabetes, but also a better understanding of diabetes – how natural history and new therapies affect the body. Type 1 diabetes (T1D) is an autoimmune disease, while type 2 diabetes (T2D) results from insulin resistance and beta cell dysfunction. In the past, the onset of these two diseases was easily identifiable. Type 1 diabetes was diagnosed almost exclusively in children, and type 2 diabetes almost always occurred in middle-aged, overweight adults. Because this distinction is obvious, researchers often do not consider laboratory confirmation of the type of diabetes, and often avoid confirmation because of the cost and difficulty of testing. Now, due to the prevalence of childhood obesity, approximately one in four newly diagnosed type 2 diabetic patients are children. Moreover, the cause is unknown, and more and more newly diagnosed patients with type 1 diabetes are adults. Delayed diagnosis of type 1 diabetes can lead to serious illness or death, so rapid diagnosis of type 1 diabetes is critical to the efficacy of emerging therapies. Type 1 diabetes is an autoimmune disease caused by an inappropriate immune system attack on healthy tissue. Therefore, the patient's body stops making insulin (a hormone that plays a key role in sugar processing). At the onset of this disease, a person's own antibodies attack the insulin-producing cells in the pancreas. Autoantibodies are present in patients with type 1 diabetes, but not in patients with type 2 diabetes. Diagnostic tests use this to distinguish them. There is growing evidence that rapid detection and aggressive new treatments for type 1 diabetes can benefit patients in the long term, may prevent autoimmune attacks on the pancreas, and maintain some of the body's ability to make insulin. Old, slow detection methods that use radioactive materials to detect autoantibodies can take several days and can only be done by trained laboratory personnel, each patient needing several hundred dollars. In contrast, the microchip does not have any radioactivity and can produce results in a matter of minutes, with minimal training. Each chip, estimated to cost about $20, can be used for more than 15 tests. Compared with the old detection method, the chip uses a smaller blood volume; it does not require laboratory blood draw, and blood can be collected by fingers. IPL Hair Removal,IPL Laser Hair Removal,IPL Hair Removal Machine,IPL Laser Hair Removal Machine Shenzhen Jie Zhong Lian Investment Co., Ltd. , https://www.szmeizons.com